Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- Onivyde (irinotecan liposomal)
- rifampin
Interactions between your drugs
rifAMPin irinotecan liposomal
Applies to: rifampin, Onivyde (irinotecan liposomal)
RifAMPin may significantly reduce the blood levels of irinotecan liposomal, which may make the medication less effective in treating your cancer. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
rifAMPin food
Applies to: rifampin
Food can decrease the levels of rifAMPin in your body. Taking rifAMPin on an empty stomach (at least 30 minutes before or 2 hours after a meal) will make it easier for your body to absorb the medication. Avoid drinking alcohol while taking rifAMPin because alcohol use may increase the risk of damage to your liver. It is important to seek immediate medical care if you experience any severe side effects or symptoms of liver damage such as fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, and/or yellowing of the skin or eyes. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Xeloda
Xeloda is used to treat breast and colorectal cancers. Learn about side effects, interactions and ...
Lynparza
Lynparza (olaparib) is used to treat ovarian cancer, breast cancer, pancreatic cancer, and prostate ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Abraxane
Abraxane is an antineoplastic medication used in the treatment breast cancer. Learn about side ...
Gemzar
Gemzar is used to treat cancers of the pancreas, lung, breasts and ovaries. Learn about side ...
Afinitor
Afinitor prevents the growth of cancer cells and is used to treat advanced kidney cancer. Learn ...
Erlotinib
Erlotinib (Tarceva) is a type of targeted therapy used to treat pancreatic cancer and non-small ...
Olaparib
Olaparib (Lynparza) is a PARP inhibitor used to treat breast cancer, prostate, ovarian, and ...
Everolimus
Everolimus (Afinitor, Afinitor Disperz, Zortress) belongs to a class of drugs called kinase ...
Gemcitabine
Gemcitabine is used for breast cancer, breast cancer, metastatic, nasopharyngeal carcinoma, non ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.